[DIFFERENCES OF EXENATIDE EFFECTS ON GLYCEMIA AND RENAL WATER AND ION EXCRETION IN FROGS AND RATS].
Zh Evol Biokhim Fiziol · 2016
Last updated 2026-08-28| Journal | Zh Evol Biokhim Fiziol, 2016 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | exenatide |
Abstract
The aim of the present study was to compare effects of glucagon-like peptide-1 (GLP-1) mimetic exenatide on glucose and water-salt homeostasis in animals with different level of renal tubular proximal reabsorption - rats (Rattus norvegicus) and frogs (Rana temporaria). Following glucose tolerance test, in rats exenatide promoted rapid recovery of normoglycemia, whereas in frogs delayed this process. In water-loaded rats exenatide essentially augmented solute-free water clearance and enhanced natriuresis in furosemide-treated rats.-In frogs exenatide did not alter urinary flow rate, urinary sodium excretion and solute-free water clearance under water diuresis and furosemide treatment. It is suggested that the invol- vement of GLP- 1 in regulation of water-salt homeostasis in mammals should be preceded by key evoluti- onary transformation - increase in glomerular filtration rate and proximal tubular reabsorption.
Verbatim abstract via PubMed 30695500 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.